Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

Benzinga Newsdesk www.benzinga.com Positive 78.8%

Neg 0% Neu 0% Pos 78.8%

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $135 to $150.